Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (191-200 of 367) with videos related to

Pageof 37
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 7, 2007
CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasoneRemco M van den Berg, H Jelle Teertstra, Nico van Zandwijk, et al.
International Journal of Cancer|August 2, 2014
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activationFloris H Groenendijk, Wouter W Mellema, Eline van der Burg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancerEgbert F Smit, Sjaak A Burgers, Bonne Biesma, et al.
Lung Cancer (Amsterdam, Netherlands)|January 30, 2013
Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancerTerry G Wiersma, Max Dahele, Wilko F A R Verbakel, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
Molecular Oncology|August 13, 2014
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stressIlya N Kotov, Ellen Siebring-van Olst, Philip A Knobel, et al.
Cancer Discovery|July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsYelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2020
Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?Pieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Cell Discovery|October 11, 2016
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancerHongde Li, William Stokes, Emily Chater, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Pageof 37

Showing results (191-200 of 367) with videos related to

Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|November 7, 2007
CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasoneRemco M van den Berg, H Jelle Teertstra, Nico van Zandwijk, et al.
International Journal of Cancer|August 2, 2014
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activationFloris H Groenendijk, Wouter W Mellema, Eline van der Burg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancerEgbert F Smit, Sjaak A Burgers, Bonne Biesma, et al.
Lung Cancer (Amsterdam, Netherlands)|January 30, 2013
Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancerTerry G Wiersma, Max Dahele, Wilko F A R Verbakel, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
Molecular Oncology|August 13, 2014
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stressIlya N Kotov, Ellen Siebring-van Olst, Philip A Knobel, et al.
Cancer Discovery|July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsYelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2020
Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?Pieter J M Joosten, Chris Dickhoff, Vincent van der Noort, et al.
Cell Discovery|October 11, 2016
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancerHongde Li, William Stokes, Emily Chater, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Pageof 37